BOTOX for treatment of vestibular migraine

Jeonbuk National University Hospital0 个研究点目标入组 20 人开始时间: 待定最近更新: 2022年2月7日

适应症

试验速览

暂无简介。

•Patients at a dizziness clinic of Jeonbuk National University Hospital, Korea, who were diagnosed with vestibular migraine(VM) using the criteria of the Headache Classification Committee of the International Headache Society (ICHD-3, appendix) and the Committee for the International Classification of Vestibular Disorders of the Bárány Society were considered for inclusion in the current study between May 2020 and January 2021. Twenty right-handed VM patients were included who suffered from moderate-to-severe vertigo attacks with migraine headache, with moderate impairment in daily life, despite treatment with several preventive drugs for at least 5 months. The use of migraine prophylactics was permitted if no changes in medications or dosages were made within the two months of study participation.

•Those who have a disease that can affect neuromuscular function, such as myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or motor neuron disease are not suitable for Botox treatment, or have been diagnosed with another primary or secondary headache disease, and patients judged unsuitable for participation in this study by the investigators were excluded.

发起方